Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?

Key Points

• Corbus stock crossed above its 50-day moving average, trading as high as $10.26 and last at $10.06 on volume of 242,941 shares (50-day MA $9.13; 200-day MA $10.24).
• Analysts are mixed but leaning positive: the consensus rating is Moderate Buy with an average price target of $43.71, while Jefferies upgraded to "strong-buy" and Oppenheimer raised its target to $57 amid several buy ratings and a few sell calls.
• Key fundamentals and ownership: Q earnings beat (EPS -$1.25 vs. -$1.78 est.), full-year EPS expected at -$4.78, market cap ~$178.5M, insiders own 3.5% (recent small sale), and institutions hold ~64.6% of the stock.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $9.13 and traded as high as $10.26. Corbus Pharmaceuticals shares last traded at $10.06, with a volume of 242,941 shares traded.

Analyst Ratings Changes

A number of research analysts have commented on CRBP shares. Jefferies Financial Group upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, February 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Monday. Oppenheimer upped their target price on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday, March 10th. Finally, Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $43.71.

Corbus Pharmaceuticals Stock Performance

The firm has a market capitalization of $178.46 million, a P/E ratio of -1.68 and a beta of 2.78. The stock has a fifty day moving average price of $9.13 and a two-hundred day moving average price of $10.24.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.53. As a group, research analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -4.78 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Dominic Smethurst sold 3,285 shares of the firm's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total value of $26,575.65. Following the sale, the insider owned 95,887 shares of the company's stock, valued at approximately $775,725.83. This trade represents a 3.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.50% of the company's stock.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CRBP. Assenagon Asset Management S.A. grew its position in shares of Corbus Pharmaceuticals by 120.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 187,956 shares of the biopharmaceutical company's stock worth $1,530,000 after acquiring an additional 102,609 shares during the last quarter. Aberdeen Group plc increased its stake in shares of Corbus Pharmaceuticals by 602.2% in the fourth quarter. Aberdeen Group plc now owns 1,321,750 shares of the biopharmaceutical company's stock valued at $10,759,000 after purchasing an additional 1,133,519 shares during the period. HighVista Strategies LLC increased its stake in shares of Corbus Pharmaceuticals by 56.8% in the third quarter. HighVista Strategies LLC now owns 118,027 shares of the biopharmaceutical company's stock valued at $1,493,000 after purchasing an additional 42,735 shares during the period. Engineers Gate Manager LP bought a new stake in shares of Corbus Pharmaceuticals during the fourth quarter valued at approximately $140,000. Finally, Laurion Capital Management LP acquired a new position in shares of Corbus Pharmaceuticals during the fourth quarter worth approximately $151,000. 64.64% of the stock is owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.